The UK competition watchdog has won permission to appeal in a case against US pharmaceutical giant Pfizer after a long-running legal battle over allegations of excessive pricing, overturning a previous decision by the Tribunal. The court said the Competition Appeal Tribunal (CAT), was “wrong to set aside the [Competition and Market’s Authority’s] decision” in relation to [...]
A panel of advisers to FDA gave its endorsement to a seasonal mRNA flu vaccine that was developed by Moderna and that earlier this year became the subject of controversy.
What Soon-Shiong has delivered, Encanta's RSV antiviral, and other biotech news from The Readout
Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer
UniQure will submit Huntington's therapy for approval, Eli Lilly buys 4E Therapeutics, and more biotech news
A cyber extortion group claimed to have stolen more than a terabyte of data from Novo Nordisk and said it is exploring selling some of the data
A new AI model to improve trial enrollment, importing drugs from Canada, and more biotech news from The Readout
Weight loss drugs will be available through Medicare starting next month, thanks to a program that is supposed to be temporary but may be difficult to end
The FDA said it will allow Colorado to import certain prescription drugs from Canada in an effort to bring prices down for residents.
After July 1, Medicare will offer GLP-1 weight-loss drugs for $50. It's supposed to be temporary, but chances are it won't be.
Covid vaccination was also tied to a nearly 24% reduction in all-cause cardiac events in a large study, surprising researchers.
A syphilis drug shortage, Sanofi's diabetes drug approval, and more biotech news from The Readout
Pfizer hasn't complied with a request to donate emergency penicillin to state health agencies as a backstop to prevent congenital syphilis
Congenital syphilis should be preventable. An Arizona case shows how drug shortages and procedural hurdles are fueling a growing public health crisis.
Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news
The nonprofit Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug, Luvelta
Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.
Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
Drug pricing in Europe, AI deals for VC firms, and more biotech news from The Readout
A new analysis found the average drug shortage in 2025 had lasted 5.3 years, exceeding the 4.3 years seen in 2024
In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.